SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of October 2018
Commission File Number 001-37410
ESSA Pharma Inc.
(Translation of registrant’s name into English)
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☐ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBITS INCLUDED AS PART OF THIS REPORT
| Exhibit | ||
| 99.1 | News release dated October 22, 2018: ESSA Appoints Otello Stampacchia, PhD., of Omega Funds to Board of Directors |
This report on Form 6-K shall be incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-225969) and Form S-8 (File No. 333-225056) under the Securities Act of 1933, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ESSAPHARMAINC. | ||||||
| (Registrant) | ||||||
| Date:October 22, 2018. | By: | /S/ DAVIDWOOD | ||||
Name: Title: | David Wood Chief Financial Officer | |||||